Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider.

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...